View More Recent Stories
-
Regenxbio (RGNX) Appoints Mitchell Chan as CFO
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
Regenxbio (RGNX) Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect
-
Regenxbio (RGNX) Tops Q2 EPS by 24c, provides guidance
-
Regenxbio (RGNX) Announces New Positive Data From Affinity Duchenne® Trial Of Rgx-202
-
RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
-
Stifel Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
Regenxbio (RGNX) Announces Expansion of AFFINITY DUCHENNE Trial
-
H.C. Wainwright Reiterates Buy Rating on Regenxbio Inc. (RGNX)
-
RBC Capital Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
-
Regenxbio (RGNX) Announces Successful Pre-BLA Meeting with FDA
-
Regenxbio (RGNX) Appoints Curran Simpson as CEO


